stockmarketproxy
/
RVMDNasdaq,Nasdaq SEC EDGAR

Revolution Medicines, Inc.

Biological Products, (No Diagnostic Substances)·REDWOOD CITY, CA·FY end 12/31·CIK 1628171
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$0$0$11.6M$35.4M$29.4M
Gross Profit——————
Operating Income-$1.2B-$689.5M-$487.2M-$258.3M-$188.0M
Net Income-$1.1B-$600.1M-$436.4M-$248.7M-$187.1M
Operating CF-$897.7M-$557.4M-$350.6M-$224.4M-$147.2M
Capex$16.0M$10.3M$7.7M$10.8M$6.5M
Free Cash Flow-$913.7M-$567.7M-$358.3M-$235.2M-$153.7M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin——-4207.1%-730.0%-639.7%
Net Margin——-3768.3%-703.0%-636.6%
FCF Margin——-3094.1%-664.8%-523.0%
R&D / Revenue——3654.1%715.3%636.1%
Effective Tax0.0%0.1%0.8%0.2%0.0%
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
RVMD
—
EXEL
81:1
GILD
119:1
BIIB
113:1
PCVX
48:1
IBRX
69:1
CEO total comp
RVMD
—
EXEL
$33M
GILD
$28M
BIIB
$24M
PCVX
$14M
IBRX
$13M
Net Margin
RVMD
—
EXEL
33.7%
GILD
28.9%
BIIB
13.1%
PCVX
—
IBRX
-310.2%